ObjectiveThis study aims to summarize the application and research progress of antibody-drug conjugates (ADC) in gastric cancer (GC). MethodWe reviewed recent domestic and international research on ADC in GC and conducted a comprehensive summary. ResultsADC was emerging as one of the most effective therapeutic options for advanced GC patients, significantly impacting the treatment and prognosis of these patients. However, their clinical application had certain limitations in some aspects. There were some kinds of ADC targeting human epidermal growth factor receptor-2, human epidermal growth factor receptor-3, guanylyl cyclase C, and trophoblasti surface antigen 2. Furthermore, the development of ADC with multiple mechanisms of action held great promise. ConclusionADC drugs represent a valuable approach for the treatment of GC and offer new perspectives and insights into the management of GC patients.
